Evans Blue Free Acid
drugOn this page
Also known as NSC-65849SID50104598SID50125877SID111068EVANS BLUEEVANS-BLUE
Summary
Evans Blue Free Acid (CHEMBL1015) is an approved small molecule.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Chemistry: 872.9 Da · C34H28N6O14S4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1015 |
| Name | Evans Blue Free Acid |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 3315 |
| Molecular formula | C34H28N6O14S4 |
| Molecular weight | 872.9 |
| InChIKey | COXVTLYNGOIATD-UHFFFAOYSA-N |
SMILES: CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)O)S(=O)(=O)O)O)C)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)O)S(=O)(=O)O)O
IUPAC name: 4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonic acid
Also known as: Evans blue free acid, NSC-65849, SID50104598, SID50125877, SID111068, EVANS BLUE, EVANS-BLUE
Parent form; salt/anhydrous children: CHEMBL1200712, CHEMBL2028479
Patent coverage: 17 distinct patent families (26 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 20 (77%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Protein deacetylase HDAC6, Menin/Histone-lysine N-methyltransferase MLL.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| HDAC6 | 5.71 | IC50 | 1955 | nM | CHEMBL_ACT_23141084 |
| MEN1 | 5.4 | Potency | 3981 | nM | CHEMBL_ACT_4563627 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.